Brandon Couillard
Stock Analyst at Wells Fargo
(3.95)
# 546
Out of 5,170 analysts
187
Total ratings
50.46%
Success rate
10.2%
Average return
Main Sectors:
Stocks Rated by Brandon Couillard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLLN BillionToOne | Maintains: Equal-Weight | $110 → $90 | $71.27 | +26.28% | 2 | Mar 5, 2026 | |
| NTRA Natera | Maintains: Equal-Weight | $205 → $215 | $197.79 | +8.70% | 4 | Feb 27, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $175 → $165 | $111.50 | +47.98% | 26 | Feb 26, 2026 | |
| RGEN Repligen | Maintains: Overweight | $190 → $180 | $117.59 | +53.07% | 4 | Feb 25, 2026 | |
| CDNA CareDx | Maintains: Equal-Weight | $18 → $21 | $17.38 | +20.83% | 5 | Feb 25, 2026 | |
| MYGN Myriad Genetics | Maintains: Equal-Weight | $6.5 → $6 | $4.64 | +29.31% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $125 | $87.27 | +43.23% | 3 | Feb 20, 2026 | |
| AVTR Avantor | Maintains: Overweight | $16 → $14 | $7.70 | +81.82% | 6 | Feb 13, 2026 | |
| WAT Waters | Maintains: Equal-Weight | $415 → $355 | $295.05 | +20.32% | 8 | Feb 11, 2026 | |
| WGS GeneDx Holdings | Upgrades: Overweight | $155 | $70.69 | +119.27% | 7 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $76 | $50.81 | +49.58% | 3 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $83 → $94 | $80.33 | +17.02% | 5 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $110 | $84.93 | +29.52% | 4 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $635 → $675 | $464.69 | +45.26% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $1,450 | $1,191.54 | +21.69% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.05 | +47.54% | 2 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $230 → $240 | $191.50 | +25.33% | 5 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $55 | $34.03 | +61.62% | 7 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $90 → $105 | $103.75 | +1.20% | 19 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $267.99 | +26.87% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $265 → $340 | $270.20 | +25.83% | 13 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $260 | $172.41 | +50.80% | 11 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $77 → $80 | $73.12 | +9.41% | 6 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $30 → $23 | $25.22 | -8.80% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.74 | +374.45% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.90 | - | 11 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $11 | $1.47 | +648.30% | 2 | Oct 13, 2017 |
BillionToOne
Mar 5, 2026
Maintains: Equal-Weight
Price Target: $110 → $90
Current: $71.27
Upside: +26.28%
Natera
Feb 27, 2026
Maintains: Equal-Weight
Price Target: $205 → $215
Current: $197.79
Upside: +8.70%
Agilent Technologies
Feb 26, 2026
Maintains: Overweight
Price Target: $175 → $165
Current: $111.50
Upside: +47.98%
Repligen
Feb 25, 2026
Maintains: Overweight
Price Target: $190 → $180
Current: $117.59
Upside: +53.07%
CareDx
Feb 25, 2026
Maintains: Equal-Weight
Price Target: $18 → $21
Current: $17.38
Upside: +20.83%
Myriad Genetics
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $6.5 → $6
Current: $4.64
Upside: +29.31%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $125
Current: $87.27
Upside: +43.23%
Avantor
Feb 13, 2026
Maintains: Overweight
Price Target: $16 → $14
Current: $7.70
Upside: +81.82%
Waters
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $415 → $355
Current: $295.05
Upside: +20.32%
GeneDx Holdings
Feb 9, 2026
Upgrades: Overweight
Price Target: $155
Current: $70.69
Upside: +119.27%
Feb 6, 2026
Maintains: Overweight
Price Target: $70 → $76
Current: $50.81
Upside: +49.58%
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $83 → $94
Current: $80.33
Upside: +17.02%
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $107 → $110
Current: $84.93
Upside: +29.52%
Dec 15, 2025
Maintains: Overweight
Price Target: $635 → $675
Current: $464.69
Upside: +45.26%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1,400 → $1,450
Current: $1,191.54
Upside: +21.69%
Dec 15, 2025
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.05
Upside: +47.54%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $230 → $240
Current: $191.50
Upside: +25.33%
Dec 15, 2025
Maintains: Overweight
Price Target: $48 → $55
Current: $34.03
Upside: +61.62%
Nov 24, 2025
Downgrades: Hold
Price Target: $90 → $105
Current: $103.75
Upside: +1.20%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $267.99
Upside: +26.87%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $265 → $340
Current: $270.20
Upside: +25.83%
Jan 23, 2025
Maintains: Buy
Price Target: $285 → $260
Current: $172.41
Upside: +50.80%
Jan 23, 2025
Maintains: Hold
Price Target: $77 → $80
Current: $73.12
Upside: +9.41%
Feb 9, 2024
Downgrades: Hold
Price Target: $30 → $23
Current: $25.22
Upside: -8.80%
Jul 13, 2021
Initiates: Buy
Price Target: $13
Current: $2.74
Upside: +374.45%
Nov 2, 2017
Downgrades: Hold
Price Target: n/a
Current: $2.90
Upside: -
Oct 13, 2017
Maintains: Buy
Price Target: $9 → $11
Current: $1.47
Upside: +648.30%